Rogers Officially Becomes Majority Owner Of Maple Leaf Sports & Entertainment
Rogers Communications closed the deal on July 1 to buy BCE's 37.5 percent stake in Maple Leaf Sports & Entertainment. It became the majority owner of the company that also owns the NBA's Toronto Raptors, CFL's Toronto Argonauts and MLS' Toronto FC.
Advertisement
Rogers announced in June it received all league approvals to buy the stake of BCE, the holding company of Bell Canada, and approval from Canada's Competition Bureau. At the time, it awaited approval from the Canadian Radio-television and Telecommunications Commission to acquire "an additional indirect interest in Toronto Raptors Network Ltd."
Now, Rogers received all necessary approvals to acquire the stake for $4.7 billion Cdn.
'MLSE is one of the most prestigious sports and entertainment organizations in the world and we're proud to be the majority owner of these iconic sports teams,' Tony Staffieri, president and CEO of Rogers, said in a news release on July 2. 'Live sports are a core part of our business and core to the fans who live and breathe every moment.'
Edward Rogers, the executive chair of Rogers Communications, told The Hockey News publisher-owner W. Graeme Roustan in January that becoming the majority owner speaks to Rogers' commitment to the Maple Leafs.
Advertisement
"Our track record is a track record of good ownership in everything we do," Rogers said in the interview for the 2025 Money & Power Issue. "We up our investments. You look at MLSE, we've won a few championships, and the vast majority of profits that MLSE makes go back into the business, back into player salaries."
Image
Rogers Communications is also the sole owner of MLB's Toronto Blue Jays.
"With the Toronto Blue Jays, we're consistently within the top 10 in terms of payroll in the league," Rogers said. "We recently invested upwards of half a billion dollars in the Rogers Centre stadium to increase the fan experience. So, we're very much investors. Ultimately, we want winning teams, and we need to invest to do that, and we know that."
Advertisement
The executive chairman also said winning teams increase viewership and value, so they're aligned with fans on the desire for squads that capture championships.
In April, the NHL and Rogers announced a new 12-year Canadian TV deal that begins after their current 12-year deal ends after the 2025-26 campaign.
The Graeme Roustan Show: Edward Rogers And Tony Staffieri
The Graeme Roustan Show: Edward Rogers And Tony Staffieri Edward Rogers, the executive chairman of Rogers Communications, and Tony Staffieri, the president-CEO of Rogers Communications, discuss their backgrounds in hockey, why the Rogers company wanted to invest in the Maple Leafs and when a Stanley Cup is coming to Toronto.
Advertisement
The Maple Leafs finished first in their division for the second time in five seasons and third time in 25 seasons, with 108 points. They advanced past the first round of the playoffs for the second time in 21 years but lost in the second round to the Florida Panthers, which went on to win their second straight Stanley Cup championship. The Marlies, meanwhile, made a first-round appearance in the AHL playoffs.
Get the latest news and trending stories by following The Hockey News on Google News and by subscribing to The Hockey News newsletter here. And share your thoughts by commenting below the article on THN.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
42 minutes ago
- Yahoo
18 Mega Stocks That Have Tanked Over the Past 10 Years: What Went Wrong
The S&P 500 is the most widely quoted proxy for the U.S. stock market, and its performance is constantly reported by the financial news. But it can sometimes be hard for investors to see the index as being composed of 500 individual stocks, rather than being a single entity. Trending Now: For You: If the S&P 500 is up 10% in any given year, for example, it's natural to assume that a stock portfolio is also up in value. But the reality is within that 10% gain, there can be a wide variety of returns, with individual stocks gaining or losing 50% or possibly even more. Over the past 10 years, most stocks in the S&P 500 have done exceedingly well, as the index as a whole posted a total return of 180.5% from June 2015 through May 2025. And while no stocks truly 'tanked' over the past decade, some did actually lose value. Against a backdrop where the overall index nearly tripled investors' money, that's essentially the same as 'tanking.' Here's a look at the unfortunate losers over the past decade, with data from Also find out the top stocks that made the most millionaires in 10 years or less. Total return over the past decade: -5.26% Total return over the past decade: -5.11% Check Out: Total return over the past decade: -2.81% Total return over the past decade: -2.76% Total return over the past decade: -2.61% Total return over the past decade: -2.50% Total return over the past decade: -2.33% Total return over the past decade: -2.24% Total return over the past decade: -2.18% Total return over the past decade: -2.12% Total return over the past decade: -1.95% Total return over the past decade: -1.93% Total return over the past decade: -1.91% Total return over the past decade: -1.39% Total return over the past decade: -0.86% Total return over the past decade: -0.96% Total return over the past decade: -1.70% Total return over the past decade: -0.14% In a 10-year period in which the overall market is screaming higher, stocks that actually lose money clearly had a problem. A number of the stocks in the above list are either real estate investment trusts or energy-related. As both of these industries underperformed the S&P 500 over the past decade, it's perhaps not surprising to see these types of stocks on the list. If those industries recover, shares of these companies should rise as well — although it will still take stock-picking prowess to sort out the winners from the losers. A company like General Mills, on the other hand, is something a bit different. The packaged foods giant has struggled mightily over the past decade, underperforming not just the overall market but its peer group of competitors, as well. This has led to a low P/E of 12.36 and a high dividend yield of 4.49%. But is this a sign of ongoing problems that will continue to drive the stock lower, or will it prove to be a value play for patient investors? Only time will tell. The bottom line is that you should always approach losing stocks with caution. It may take some level of analysis, either on your own or in conjunction with a financial advisor, to determine if a crashing stock is a value opportunity — or a value trap. More From GOBankingRates Warren Buffett: 10 Things Poor People Waste Money On This article originally appeared on 18 Mega Stocks That Have Tanked Over the Past 10 Years: What Went Wrong Sign in to access your portfolio
Associated Press
an hour ago
- Associated Press
Clearmind Medicine Announces IRB Approval for Phase 1/2a Clinical Trial for Alcohol Use Disorder at Tel Aviv Sourasky Medical Center
Vancouver, Canada, July 03, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ('Clearmind' or the 'Company'), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that it has received Institutional Review Board (IRB) approval from Tel Aviv Sourasky Medical Center (TASMC) in Tel Aviv, Israel, for its ongoing Phase 1/2a clinical trial evaluating CMND-100, a proprietary MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD). This approval will enable patient enrollment at TASMC, a leading clinical site in Israel, prior to commencing this first-in-human trial at the site. The trial includes other first-in-class institutions, such as Yale School of Medicine's Department of Psychiatry, Johns Hopkins University School of Medicine and Hadassah-University Medical Center in Jerusalem, Israel. The study at TASMC will be led by Dr. David Zeltser, Director of the Emergency Medicine Department and Deputy Director R&D and Innovation. Clearmind recently announced the dosing of the first participant in the trial, marking a historic step toward developing a novel therapy for the millions affected by AUD worldwide. IRB approval from TASMC follows Clearmind's prior regulatory milestones, including U.S. Food and Drug Administration (FDA) clearance of its Investigational New Drug (IND) application and IRB approvals from other clinical sites. 'We are pleased to receive IRB approval from Tel Aviv Sourasky Medical Center, a renowned institution, for our Phase 1/2a clinical trial,' said Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine. 'This milestone brings us closer to potentially offering a transformative treatment for individuals struggling with AUD, a condition that devastates millions of lives. With TASMC's participation, alongside leading centers like Yale and Johns Hopkins, we believe that we are well-positioned to advance our mission of developing safe, effective, and innovative psychedelic-derived therapies.' Clearmind's clinical trial is a critical step in addressing the global burden of AUD, which accounts for 4.7% of all deaths worldwide, according to the World Health Organization. The Company anticipates further progress in patient enrollment and data collection across its clinical sites, with the goal of delivering a breakthrough solution for those affected by AUD and their families. The Phase 1/2a clinical trial, a multinational, multi-center study, is designed to assess the safety, tolerability, and pharmacokinetic profile of CMND-100, while also evaluating its preliminary efficacy in reducing alcohol cravings and consumption in patients with AUD. About Clearmind Medicine Inc. Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements. The Company's intellectual portfolio currently consists of nineteen patent families including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio. Shares of Clearmind are listed for trading on Nasdaq under the symbol 'CMND' and the Frankfurt Stock Exchange under the symbol 'CWY0.' For further information visit: or contact: Investor Relations [email protected] Telephone: (604) 260-1566 US: [email protected] General Inquiries [email protected] Forward-Looking Statements: This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as 'expects,' 'anticipates,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates' and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses potentially offering a transformative treatment for individuals struggling with Alcohol Use Disorder, its belief that it is well-positioned to advance its mission of developing safe, effective, and innovative psychedelic-derived therapies and its anticipation of further progress in patient enrollment and data collection across its clinical sites, with the goal of delivering a breakthrough solution for those affected by AUD and their families. Forward-looking statements are not historical facts, and are based upon management's current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management's expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company's reports filed from time to time with the Securities and Exchange Commission ('SEC'), including, but not limited to, the risks detailed in the Company's annual report on Form 20-F for the fiscal year ended October 31, 2024 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.
Fox News
an hour ago
- Fox News
White House reveals highest-paid staffers--and 8 taking no salaries
President Donald Trump's administration released its annual report revealing the salaries for every staffer inside the White House on Thursday. The report shows employees' earnings in a range of $59,070 at the lowest to $225,700 at the highest, though a few aren't accepting salaries at all. The top-paid staffer at the White House is Jacalynne Klopp, a senior adviser and the sole staffer earning $225,700. Behind her is Edgar Mkrtchian, an associate counsel making $203,645. Behind them comes a group of 33 staffers making $195,200, which includes many well-known names. White House press secretary Karoline Leavitt takes in this level of salary, as does border czar Tom Homan, chief of staff Susan Wiles, trade adviser Peter Navarro, communications director Steven Cheung, and homeland security adviser Stephen Miller. The White House did not immediately respond to a request for comment from Fox News Digital. According to the report, there are 108 employees who make between $59,000 and $80,000, while Trump's speechwriters earn between $92,500 and $121,500. Eight employees do not receive salaries at all, though some of those are due to overlapping roles in other sections of government. Secretary of State Marco Rubio is chief among these, not receiving any compensation for his White House role as national security adviser. Special envoy Steve Witkoff also receives compensation from the state department rather than the White House. Trump's own compensation is not listed in the report, but the pay scheme for the president is laid out in federal law. As president, Trump earns a base salary of $400,000, as well as a $50,000 expense allowance, $100,000 for travel, and $19,000 for entertainment. Trump donated his salary to government agencies during his first term in office, but he has not clarified whether he will do the same during his second term. The White House did not immediately respond when asked about Trump's compensation.
